

Original Article

Diagnostic Immunology



Ann Lab Med 2016;36:542-549
<http://dx.doi.org/10.3343/alm.2016.36.6.542>

ISSN 2234-3806 · eISSN 2234-3814

ANNALS OF LABORATORY MEDICINE

Soluble ST2 Levels and Left Ventricular Structure and Function in Patients With Metabolic Syndrome

Vera Celic, Ph.D.^{1,2}, Anka Majstorovic, M.D.², Biljana Pencic-Popovic, Ph.D.^{1,2}, Aleksandra Slijivic, M.D.², Natalia Lopez-Andres, Ph.D.³, Ignacio Roy, M.D.⁴, Elena Escribano, M.D.⁴, Maite Beunza, M.D.⁴, Amaia Melero, M.D.³, Federico Floridi, M.D.⁵, Laura Magrini, M.D.⁵, Rossella Marino, M.D.⁵, Gerardo Salerno, Ph.D.⁵, Patrizia Cardelli, Ph.D.⁵, and Salvatore Di Somma, Ph.D.⁵

Faculty of Medicine¹, University of Belgrade, Belgrade, Serbia; University Hospital Centre "Dr Dragisa Misovic-Dedinje"², Belgrade, Serbia; Miguel Servet Foundation-Navarrabiomed³, Pamplona, Spain; Complejo Hospitalario de Navarra⁴, Pamplona, Spain; School of Medicine and Psychology⁵, La Sapienza University, Sant'Andrea Hospital, Rome, Italy

Background: A biomarker that is of great interest in relation to adverse cardiovascular events is soluble ST2 (sST2), a member of the interleukin family. Considering that metabolic syndrome (MetS) is accompanied by a proinflammatory state, we aimed to assess the relationship between sST2 and left ventricular (LV) structure and function in patients with MetS.

Methods: A multicentric, cross-sectional study was conducted on 180 MetS subjects with normal LV ejection fraction as determined by echocardiography. LV hypertrophy (LVH) was defined as an LV mass index greater than the gender-specific upper limit of normal as determined by echocardiography. LV diastolic dysfunction (DD) was assessed by pulse-wave and tissue Doppler imaging. sST2 was measured by using a quantitative monoclonal ELISA assay.

Results: LV mass index ($\beta=0.337$, $P<0.001$, linear regression) was independently associated with sST2 concentrations. Increased sST2 was associated with an increased likelihood of LVH [Exp (B)=2.20, $P=0.048$, logistic regression] and increased systolic blood pressure [Exp (B)=1.02, $P=0.05$, logistic regression]. Comparing mean sST2 concentrations (adjusted for age, body mass index, gender) between different LV remodeling patterns, we found the greatest sST2 level in the group with concentric hypertrophy. There were no differences in sST2 concentration between groups with and without LV DD.

Conclusions: Increased sST2 concentration in patients with MetS was associated with a greater likelihood of exhibiting LVH. Our results suggest that inflammation could be one of the principal triggering mechanisms for LV remodeling in MetS.

Key Words: Soluble ST2, Metabolic syndrome, Echocardiography, Left ventricular hypertrophy

Received: February 28, 2016

Revision received: May 14, 2016

Accepted: July 27, 2016

Corresponding author: Salvatore Di Somma
 University La Sapienza Rome, Sant'Andrea Hospital, Via di Grottarossa 1035/1039
 00189 Rome, Italy
 Tel: +3906-33775581
 Fax: +3906-33775890
 E-mail: salvatore.disomma@uniroma1.it

© The Korean Society for Laboratory Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Metabolic syndrome (MetS) is a group of the most common cardiovascular disease (CVD) risk factors: raised fasting plasma glucose, abdominal obesity, dyslipidemia and hypertension, as well as genetics, aging, and a proinflammatory state, which

have been shown to increase cardiovascular (CV) morbidity and mortality [1, 2]. The association between MetS and adverse CV outcomes is independent of diabetes mellitus (DM) and arterial hypertension [3]. In addition, MetS has been associated with changes in cardiac structure and function, including left ventricular (LV) hypertrophy and subclinical LV systolic and/or dia-

stolic dysfunction [4]. Alterations in LV structure and function of patients with MetS could be an important link to CV morbidity and mortality [3]. The prevalence of LV hypertrophy (LVH) and LV dysfunction significantly increased with the presence of an increasing number of risk factors [5]. One of the factors that certainly contributes to MetS is a proinflammatory state. A biomarker that is currently of interest in relation to this is soluble ST2 (sST2), a member of the interleukin (IL)1 receptor host defense and inflammation family [6, 7].

In patients with increased sST2 concentrations, protective functions of IL-33 may be inhibited, leading to maladaptive cardiac remodeling with fibrosis, hypertrophy, and loss of function [8]. Recently, sST2 has been reported to be increased in patients with heart failure, myocardial infarction, hypertension, severe obesity, and diabetes [9-14]. sST2 emerged as a prognostic biomarker for both nonfatal cardiac events and mortality in high-risk patients [15]. With regards to LV remodeling in MetS, there is no available data on sST2 concentrations and their possible influence on LV structure and function.

The aim of the present study was to determine the link between proinflammatory factors, namely sST2, and LV remodeling in patients with MetS, as a potentially useful tool in early assessment of MetS patients.

METHODS

A multicentric, cross-sectional study was conducted at university hospital centers in Italy, Serbia, and Spain, from April 2013 to October 2014.

The study included 180 consecutive subjects who were referred from outpatient clinics where they were screened for MetS. The study was conducted in compliance with the Declaration of Helsinki, and the Ethics Committees of all the institutions where research was conducted approved the research protocol. Informed consent was obtained from all subjects.

Demographic and clinical parameters of the study population are presented in Table 1.

The study group included almost equal proportions of men and women, aged less than 65 yr, exhibiting central obesity and the other MetS criteria. About 94% of the subjects had hypertension, with an average therapy duration of seven years. Diabetes was present in 25% of subjects, with an average duration of less than two years.

All participants underwent physical, laboratory, and echocardiographic examinations.

Arterial blood pressure (BP) was obtained by taking the average value from at least two BP measurements in the sitting position within a 1-2 min interval [16]. Anthropometric measure-

Table 1. Demographic characteristics and clinical parameters of the study population

Variables	n = 180	Variables	n = 180
Age (yr)	52.63 ± 8.95	CCB	72 (40%)
Heart rate (1/min)	72.07 ± 12.22	Diuretics	73 (40.6%)
Gender (males)	93 (51.7%)	Lipid lowering therapy	72 (40%)
SBP (mm Hg)	139.55 ± 18.48	Plasma glucose (mmol/L)	6.03 ± 1.67
DBP (mm Hg)	83.96 ± 12.31	HbA1c (mmol/L)	6.12 ± 0.95
Waist circumference (cm)	102.85 ± 10.10	Cholesterol (mmol/L)	5.46 ± 1.23
BMI (kg/m ²)	30.58 ± 4.77	HDL cholesterol (mmol/L)	1.16 ± 0.40
BSA (m ²)	2.01 ± 0.21	LDL cholesterol (mmol/L)	3.44 ± 1.10
DM	45 (25%)	Triglycerides (mmol/L)	2.13 ± 1.49
DM duration (yr)	1.89 ± 4.44	Serum creatinine (μmol/L)	72.62 ± 18.22
HTA	169 (93.9%)	eGFR (mL/min)	123.48 ± 37.87
HTA duration (yr)	7.01 ± 4.83	Potassium (mmol/L)	4.41 ± 0.39
ACEi	105 (58.3%)	Sodium (mmol/L)	139.96 ± 3.18
ARB	43 (23.9%)	Hb (g/L)	142.78 ± 15.38
BB	79 (43.9%)	ST2 (ng/mL)	27.35 ± 15.74

Data are presented as mean ± SD or n (%).

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; BSA, body surface area; DM, diabetes mellitus; HTA, hypertension; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, β blocker; CCB, calcium channel blocker; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration ratio.

ments (height, weight, waist circumference) were taken for all subjects. Body surface area (BSA) and body mass index (BMI) were calculated. Regarding MetS and laboratory analyses, we determined the levels of fasting glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, and triglycerides. Additional laboratory tests included analyzing hemoglobin, sodium, and potassium levels, as well as measures of renal function (creatinine and glomerular filtration rate). All study participants underwent biomarker testing for N-terminal pro-hormone B-type natriuretic peptide (NT-proBNP) and sST2. Samples were collected from each patient and stored at -25°C . They were transported via airplane on dry ice without any delay during transportation, and processed at a local laboratory in Rome upon arrival. Levels of sST2 were stable during the transportation process.

MetS was diagnosed according to the new International Diabetes Federation (IDF) definition as the presence of central obesity and at least two of the following factors: triglycerides ≥ 1.7 mmol/L (or specific treatment for this lipid abnormality), HDL cholesterol < 1.03 mmol/L in males and < 1.29 mmol/L in females (or specific treatment for this lipid abnormality), systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg (or treatment of previously diagnosed hypertension), and fasting plasma glucose ≥ 5.6 mmol/L. Central obesity was assumed if BMI was > 30 kg/m², or waist circumference was ≥ 102 cm in males and ≥ 88 cm in females [17, 18].

Study inclusion criteria consisted of MetS, age < 65 yr, normal LV ejection fraction (EF) ($\geq 50\%$), and normal concentration of NT-proBNP. Exclusion criteria were: symptoms or signs of heart failure, cardiac arrhythmia with hemodynamic instability, documented coronary artery disease, previous cerebrovascular events, congenital or valvular heart disease, liver cirrhosis, kidney failure, anemia, malignant disease, and alcoholism.

The duration of hypertension was defined by the length of antihypertensive drug usage. The duration of diabetes was defined by the length of the specific therapy regimen.

1. Laboratory assays

All patients underwent sST2 testing at admission. Blood samples from all centers were shipped to the central laboratory in Rome. Testing was performed by using Presage ST2 (Critical Diagnostics, San Diego, CA, USA), a quantitative monoclonal ELISA assay in a 96-well plate (ELISA PLATE READER DAS S.R.L.; model A3 and C, Rome, Italy). In each well, we added 100 μL of blood serum. Normal sST2 values for patients in good health are divided by sex as follows: 23.6 ± 2.3 ng/mL for men

and 16.2 ± 1.2 ng/mL for women.

2. Echocardiographic study

Echocardiographic images were obtained by using a 2.5-MHz transducer with harmonic capability, in all centers, using a Vivid 7 (General Electric, Boston, MA, USA) echo machine. A complete two-dimensional echocardiographic (2DE) study was performed in the left lateral decubitus position, according to recommendations from the American Society of Echocardiography (ASE) [19]. Reported values of all echocardiographic parameters represent the average value of three consecutive cardiac cycles.

Relative wall thickness (RWT) was calculated as $(2 \times \text{LV posterior wall thickness}) / \text{LV internal end-diastolic diameter}$. LV end-systolic and end-diastolic volumes and EF were calculated by using the biplane method. Left atrial (LA) volume was calculated by using the LA areas and lengths measured from both the apical four- and two-chamber views. LV and LA volumes were indexed by BSA. For calculating LV mass, we used a formula proposed by Devereux and colleagues (ASE): $\text{LV mass} = 0.8 (1.04 [(\text{LVIDD} + \text{PWTD} + \text{IVSTD})^3 - (\text{LVIDD})^3]) + 0.6$ g, where IVSTD is the diastolic interventricular septum thickness, PWTD is the diastolic posterior wall thickness, and LVIDD is the LV internal diastolic diameter [19]. LV mass was indexed by BSA (LV mass index [LVMI]). LV hypertrophy was defined by LVMI ≥ 116 and ≥ 96 g/m² in men and women, respectively. Remodeling patterns of LV were categorized regarding RWT and LVMI as: normal LV geometry, normal LVMI and RWT ≤ 0.42 ; concentric remodeling, normal LVMI with increased RWT > 0.42 ; concentric hypertrophy, increased LVMI and increased RWT > 0.42 ; eccentric remodeling, increased LVMI and RWT ≤ 0.42 [19]. Transmitral pulsed Doppler inflow included measurements of early diastolic mitral flow velocity (E), deceleration time (DT), late diastolic mitral flow velocity (A), and E/A ratio [20]. Tissue Doppler imaging was used in the apical 4-chamber view with a sample volume placed at the septal and lateral segment of the mitral annulus during early and late diastole (e' and a'). The average of the peak early diastolic relaxation velocity (e') was calculated, as well as the E/e' average ratio [20]. Doppler timed LV interval (in milliseconds), the isovolumic relaxation time (IVRT), was measured with continuous Doppler by aiming the Doppler beam at an intermediate position between inflow and outflow to record both velocities. IVRT was measured as the interval between the end of ejection and the onset of mitral inflow [20]. Left ventricular internal diameter-diastole LVIDD was assessed by Doppler parameters (E/A ratio, DT, e' lateral, e' septal), following the recommendations of

the European and the American Society of Echocardiography [21, 22].

3. Statistical analyses

Continuous variables are presented as mean±SD. Normality of data sets was assessed by the Kolmogorov-Smirnov test. When data did not follow normality assumptions and non-normality was due to a valid reason (real observed data points of sST2), data were transformed to obtain normality by applying a logarithmic transformation (LogsST2). An independent samples t-test was used to compare means from two groups. Differences in proportions were compared by using a chi-square test. Pearson's correlation coefficients were used for determining the correlation between 2D LV parameters, sST2, and the other parameters. *P* values <0.05 (two-sided) were considered statistically significant. The variables that showed *P* values ≤ 0.10 were included into the stepwise linear regression analysis. A logistic regression was performed to determine the effects of different parameters on the likelihood that participants had LVH and LVDD. A general linear model and the analysis of equal variance with Bonferroni post hoc analysis were used to detect differences between four groups of LV remodeling patterns. The accuracy of the sST2 test for distinguishing between patients with and without LVH was assessed from ROC curve analysis.

RESULTS

sST2 concentrations were increased above normal values in the study group as a whole. In addition to the mean value of sST2 listed in Table 1, the median concentration of sST2 for the group was 23 ng/mL.

Regarding MetS parameters as inclusion criteria, all participants, males and females, had similar systolic BP (SBP), diastolic BP (DBP), and plasma glucose levels. Males were younger, with higher BMI and waist circumference than females, and had higher levels of serum triglycerides on average. Females had higher levels of HDL (Table 2).

Results of 2D echocardiographic examinations of LV structure and function in subjects with MetS are shown in Table 3. Mean values of LA dimensions, LV volumes, and EFs were normal. There was an increased diastolic thickness of the septum and posterior wall, as well as an increased relative wall thickness. Overall, parameters of LV diastolic function (E/A , e'/a' average, E/e' average) were impaired in study participants.

Correlation analysis demonstrated that HDL ($r=-0.188$, $P=0.022$), IVSTD ($r=0.185$, $P=0.023$), PWTd ($r=0.225$, $P=$

Table 2. Metabolic syndrome parameters and soluble ST2 (sST2) concentration in study participants

Variable	Gender	Mean	<i>P</i>
Age (yr)	Male	50.47 ± 9.23	0.001
	Female	55.10 ± 7.93	
SBP (mm Hg)	Male	139.38 ± 17.37	0.902
	Female	139.73 ± 19.69	
DBP (mm Hg)	Male	85.26 ± 13.03	0.126
	Female	82.59 ± 11.41	
BMI (kg/m ²)	Male	31.82 ± 4.49	0.000
	Female	29.25 ± 4.72	
Waist circumference (cm)	Male	107.06 ± 8.21	0.001
	Female	99.72 ± 10.25	
Plasma glucose (mmol/L)	Male	6.09 ± 1.76	0.642
	Female	5.97 ± 1.56	
HDL cholesterol (mmol/L)	Male	1.02 ± 0.29	0.000
	Female	1.31 ± 0.45	
Triglycerides (mmol/L)	Male	2.38 ± 1.78	0.016
	Female	1.85 ± 1.04	
sST2 (ng/mL)	Male	26.24 ± 13.88	0.336
	Female	28.73 ± 17.81	

Data are presented as mean±SD.

Abbreviations: See Table 1.

0.006), LV mass ($r=0.286$, $P=0.000$), LVMI ($r=0.304$, $P=0.000$), DT ($r=-0.181$, $P=0.029$), and IVRT ($r=-0.228$, $P=0.008$) were significantly related to sST2, but correlation coefficient was relatively weak.

When these parameters were added in the linear regression model, stepwise method, only LVMI ($\beta=0.337$, $P=0.000$), IVRT ($\beta=-0.256$, $P=0.002$), and HDL ($\beta=-0.199$, $P=0.013$) were independently associated with sST2 concentrations, which is shown graphically in Fig. 1.

LVH was found in 48 (26.7%) subjects. LVMI was normal in 132 (73.3%) subjects. sST2 was significantly higher in patients with LVH than in patients without LVH (32.18 ± 16.88 ng/mL vs 25.94 ± 15.19 ng/mL, $P=0.042$).

A logistic regression was performed to determine the effects of age, BMI, gender, SBP, DBP, therapy, and sST2 concentration on the likelihood of participants having LVH. The logistic regression model was statistically significant ($\chi^2=9.65$, $P=0.008$). The model correctly classified 89% of cases. Increased sST2 concentration was associated with an increased likelihood of exhibiting LVH [Exp (B)=2.20, $P=0.048$] as well as increased SBP [Exp (B)=1.02, $P=0.05$]. Males with MetS were 2.51 times more likely to exhibit LVH than females ($P=0.001$).

Table 3. Two-dimensional echocardiographic (2DE) parameters of left ventricular structure and function in the study population

2DE variables	Value
Left atrial diameter (mm)	39.27 ± 4.61
Interventricular septum thickness (mm)	10.40 ± 1.52
Posterior wall thickness (mm)	10.31 ± 1.36
LV end-diastolic diameter (mm)	48.55 ± 5.70
LV end-systolic diameter (mm)	32.08 ± 5.42
Relative wall thickness (cm)	0.43 ± 0.08
LV mass (g)	182.02 ± 44.60
LV mass index (g/m ²)	90.63 ± 20.90
LV end-diastolic volume (mL)	104.53 ± 28.13
LV EDVi (mL/m ²)	52.42 ± 13.91
LV end-systolic volume (mL)	42.37 ± 15.17
ESVi (mL/m ²)	21.15 ± 7.22
EF biplane (%)	60.56 ± 6.61
Left atrial volume (mL)	45.82 ± 22.88
Left atrial volume/BSA (mL/m ²)	22.77 ± 10.93
E (m/s)	0.70 ± 0.17
A (m/s)	0.74 ± 0.18
E/A	0.99 ± 0.33
DT (ms)	214.49 ± 48.99
IVRT (ms)	82.45 ± 23.75
e _{septal} (m/s)	0.07 ± 0.02
e _{lateral} (m/s)	0.10 ± 0.07
e _{average} (m/s)	0.08 ± 0.04
a _{septal} (m/s)	0.10 ± 0.02
a _{lateral} (m/s)	0.11 ± 0.03
a _{average} (m/s)	0.10 ± 0.02
E/e _{average}	8.37 ± 2.84
e _{lateral} /a _{average}	0.85 ± 0.39

Data are presented as mean ± SD.

Abbreviations: See Table 1; LV, left ventricular; EDVi, end-diastolic volume indexed by BSA; ESVi, end-systolic volume indexed by BSA; A, late diastolic mitral flow (pulse Doppler); E, early diastolic mitral flow (pulse Doppler); IVRT, isovolumic relaxation time; DT, deceleration time; e_{lateral}, peak early diastolic relaxation velocity of the lateral mitral annulus (tissue Doppler); a_{lateral}, peak late diastolic relaxation velocity of the lateral mitral annulus (tissue Doppler).

We performed ROC analysis for sST2, and the classification variable was LVH. ROC analysis showed that testing for sST2 has the ability to distinguish between the two groups; the area under the ROC was 0.62, *P*=0.02 (95% confidence interval [CI]: 0.557, 0.724). This relatively low area under the ROC in our study indicates that non-invasive risk scores regarding LVH and sST2 concentrations in patients with MeS needs further re-




Fig. 1. Partial regression plot: Relation between soluble ST2 (sST2) and two-dimensional echocardiographic left ventricular (LV) mass index.




Fig. 2. ROC: Sensitivities and specificities of the soluble ST2 criteria for left ventricular hypertrophy determined by two-dimensional echocardiography.

finement and testing (Fig. 2).

Youden index was criteria used to find the optimal sST2 threshold point (>30.94) from the ROC curve for sST2 and increased LVMI, with CI of 14.81-49.76, sensitivity of 44.12%, and specificity of 77.78%.

Comparing mean concentrations of sST2 between different remodeling patterns of LV, using GLM, we found the highest sST2 concentration in the group of subjects with concentric hypertrophy (Table 4).

Among study participants, 101 (56.1%) subjects had impaired

Table 4. Serum soluble ST2 (sST2) level differences between patterns of left ventricular remodeling (fixed factor), adjusted for age, body mass index (covariates), and gender (random factor)

Variable	Normal LV geometry (n=64)	Concentric LV remodeling (n=68)	Concentric LV hypertrophy (n=20)	Eccentric LV remodeling (n=28)
sST2 (ng/mL)	23.94 ± 2.26*	27.53 ± 1.92 [†]	41.16 ± 4.15	27.48 ± 3.69

Data are presented as mean ± SD; Adjustment for multiple comparisons: Bonferroni; mean difference is significant at the 0.05 level.

*normal LV remodeling vs concentric LV hypertrophy ($P=0.003$); [†]concentric LV remodeling vs concentric LV hypertrophy ($P=0.019$).

Abbreviation: LV, left ventricular.

LV DD. Regardless of sST2 correlating with IVRT as the parameter of LV DD, there were no differences in the mean sST2 serum concentration between groups with and without LV DD (29.77 ng/mL ± 15.87 ng/mL vs 25.85 ng/mL ± 15.16 ng/mL, $P=0.303$). LV DD was linked to SBP [Exp (B)=1.19, $P=0.05$], age [Exp (B)=1.19, $P=0.001$], and LVMI [Exp (B)=1.044, $P=0.045$].

DISCUSSION

The principal finding of the present study was that sST2 concentration increased in patients with MetS, and was significantly related to LV remodeling. The serum concentration of sST2 in MetS patients was not linked to age, gender, or history of hypertension or diabetes. In addition, we did not find a significant correlation with most of MetS factors: BMI, waist circumference, BP, plasma glucose and triglycerides.

In The Dallas Heart Study (DHS), sST2 concentrations were not significantly associated with most traditional CV risk factors or subclinical CV disease [15]. In the Framingham heart study (FHS), sST2 concentrations differed between men and women, increased with age, and were associated with diabetes and hypertension [11]. The DHS and the FHS were large, population-based studies. In the study by Ojji *et al* [12], BP in hypertension patients did not differ significantly between four groups of LV remodeling patterns. Therefore, BP did not influence sST2 concentration, which was higher in the concentric hypertrophy group. The results of the study conducted by Fousteris *et al* [14] indicate that type 2 diabetes is associated with higher sST2 concentrations, which are positively correlated with CRP levels and the extent of glycemic control. In this study, there was a control group with normal glucoregulation, while the MetS study did not include controls. Our results are related to a specific group of patients with MetS, which, by definition, already includes risk factors and their interactions. This could explain the lack of correlation between sST2 and risk factors. sST2 was recently shown to be expressed in adipose tissue macrophages [13, 23]. Waist circumference and BMI of our patients were in accordance with MetS criteria for central obesity.

We demonstrated that parameters of LV structure and sub-clinical DD were considerably related to sST2. Among the dysfunction parameters, only LVMI and IVRT were independently associated with sST2 concentration. Increased sST2 concentration was associated with an increased likelihood of exhibiting LVH, as well as increased SBP. In addition, LVH was gender-related: males with MetS were 2.5 times more likely to show LVH than females. Elevated BP and hormones are well known predictors of LVH. Our results indicate that the proinflammatory state as determined by elevated sST2 is a more powerful LVH contributing factor than SBP in MetS.

The mechanism of sST2 action in the heart is not fully understood. ST2 is a member of the IL-1 receptor family. The gene encoding ST2 is clearly upregulated in cardiomyocytes and fibroblasts during mechanical stretch [7, 9]. This gene encodes a protein that consists of a functionally active (via binding to IL-33) transmembrane ST2 receptor form (ST2L) and a soluble receptor form (sST2) that can be detected in serum [8]. Cardiomyocytes and cardiac fibroblasts show a concordant increase in release of both ST2L and sST2 under biomechanical strain [8]. This release is an important step in the overall mechanism of inducing cardiac remodeling due to volume and/or pressure overload [24]. The pitfall of this action lies in the fact that presence of large amounts of sST2 may be a “decoy” receptor, acting as a sort of “off switch” for ST2/IL-33 signaling [8]. In the context of CV damage, ST2L/IL-33 reduces cardiac remodeling, fibrosis, and hypertrophy. Possibly, IL-33 can exert an antihypertrophic effect by preventing the actions of angiotensin II or phenylephrine on myocardium [24]. It was recently shown that in CVD models, IL-33 reduces atherosclerotic plaque formation or cardiac hypertrophy secondary to pressure overload [25]. These protective effects of ST2L/IL-33 on cardiac remodeling could be blocked by the presence of large amounts of sST2 competing for IL-33. At the same time, released IL-33 is recognized by different immune cells that produce proinflammatory mediators, and can induce endothelial activation. Both macrovascular (aortic and coronary artery) and heart microvascular endothelial cells are sources of sST2 protein [26].

This situation with modulated proinflammatory response could easily be translated to other similar scenarios of increased volume and/or pressure overload and impaired overall homeostasis, such as MetS.

Our results confirmed that increased sST2 concentrations in MetS were associated with LV remodeling. sST2 concentrations were significantly elevated in MetS patients with LVH, and the highest sST2 concentrations were found in the group of MetS subjects with concentric hypertrophy, which agrees with the results of the study by Ojji *et al* [12]. This author, in the group of hypertensive patients, showed that sST2 is a useful biomarker for distinguishing hypertensive LVH from hypertension without LVH [12]. We also showed that increased sST2 concentrations could be helpful for making a distinction between MetS patients with and without LVH, but the area under the ROC was 0.62, implying relatively poor accuracy, and the optimal cut-off value of sST2 had low sensitivity.

Regarding LV function, parameters of diastolic function were generally impaired in patients with MetS. Even though sST2 concentration correlated with IVRT, there was no difference in sST2 concentration between groups with and without LVDD. A greater likelihood of having impaired LV diastolic function was seen in MetS patients who were older, had increased SBP, and had increased LVMI. This result is in accordance with the findings of Wang *et al* [27] in a group of hypertensive patients. Authors reported a poor correlation between sST2 concentration and diastolic parameters in hypertensive patients with stable heart failure and normal LV EF.

A limitation of the present study is that it does not have an inherent temporal dimension, because it was a cross-sectional study. We recognize that the lack of follow-up data could be a limitation of this study regarding the prognostic significance of our results.

To our knowledge, the present study is the first to examine the relationship between sST2 and LV structure and function in patients with MetS. An increased sST2 concentration in patients with MetS was associated with a greater likelihood of exhibiting LVH. sST2 was a more powerful predictor for LVH than SBP. Our results suggest that inflammation could be one of the principal triggering mechanisms for LV remodeling in MetS. According to our findings, sST2 might be a useful biomarker in the early assessment of LV remodeling in MetS. Future studies on the prognostic utility of sST2 and therapeutic strategies targeted toward the IL family in MetS are necessary.

Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation 2006.
2. Hunt KJ, ResendezRG, Williams K, Haffner SM, Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. *Circulation* 2004;110:1251-7.
3. Kim SH. Metabolic syndrome and myocardial contractile reserve. *J Cardiovasc Ultrasound* 2011;19:174-5.
4. de las Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler RJ, et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. *Eur Heart J* 2007;28:553-9.
5. Tadic M, Ivanovic B, Kostic N, Simic D, Matic D, Celic V. Metabolic syndrome and left ventricular function: is the number of criteria actually important? *Med Sci Monit* 2012;18:282-9.
6. O'Neil L. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. *BiochemSoc Trans* 2000;28:557-63.
7. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. *Circulation* 2004;109:2186-90.
8. Rehman SU, Mueller T, JanuzziJL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. *J Am CollCardiol* 2008;52:1458-65.
9. Weinberg EO, Shimpo M, De KeulenaerGW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. *Circulation* 2002;106:2961-6.
10. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. *Circulation* 2003;107:721-6.
11. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. *Clin Chem* 2012;58:1673-81.
12. Ojji DB, Opie LH, Lecour S, Lacerda L, Adeyemi O, Sliwa K. Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients. *J Clin Hypertens* 2013;15:899-904.
13. Zeyda M, Wernly B, Demyanets S, Kaun C, Hämmerle M, Hantusch B, et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. *Int J Obes* 2013;37:658-65.
14. Fousteris E, Melidonis A, Panoutsopoulos G, Tzirogiannis K, Foussas S, Theodosis-Georgilas A, et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. *Cardiovasc Diabetol* 2011;10:101.

15. Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. *Clin Chem* 2013;59:536-46.
16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2013;34:2159-219.
17. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120:1640-5.
18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006;23:469-80.
19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015;28:1-39.
20. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA; Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. *J Am Soc Echocardiogr* 2002;15:167-84.
21. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *Eur J Echocardiogr* 2009;10:165-93.
22. Oh JK, Park SJ, Nagueh SF. Established and novel clinical applications of diastolic function assessment by echocardiography. *Circ Cardiovasc Imaging* 2011;4:444-55.
23. Westcott DJ, Delproposto JB, Geletka LM, Wang T, Singer K, Saltiel AR, et al. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. *J Exp Med* 2009;206:3143-56.
24. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: a review. *Molecules* 2013;18:15314-28.
25. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. *Immunity* 2013;39:1003-18.
26. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. *J Mol Cell Cardiol* 2013;60:16-26.
27. Wang YC, Yu CC, Chiu FC, Tsai CT, Lai LP, Hwang JJ, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. *J Card Fail* 2013;19:163-8.